Unlocking the epigenetic code: future Frontiers in predictive biomarkers for intellectual disability in fragile X syndrome.

Fragile X Syndrome (FXS) remains the leading inherited cause of intellectual disability (ID), yet the classic CGG repeat expansion on the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene often fails to provide a precise prognostic map for cognitive outcomes. While the expansion is the primary trigger, the resulting epigenetic landscape, characterized by DNA hypermethylation and chromatin remodelling, is the true driver of gene silencing and phenotypic severity. This review critically evaluates the shift from traditional genetic screening to advanced epigenetic profiling as a robust framework for predicting ID in FXS. We synthesize emerging evidence on how quantitative epigenetic signatures can bridge the gap between genotype and the heterogeneous cognitive phenotypes observed in clinical practice. We explore the architecture of FMR1 silencing, emphasizing the role of mosaicism and epigenetic heterogeneity in shaping neurodevelopmental trajectories. A significant focus is placed on cutting-edge technologies, including single-cell epigenomics and CRISPR/dCas9-mediated epigenetic editing, which are transforming our ability to quantify 'epigenetic load.' Furthermore, we discuss the integration of machine learning algorithms to analyze multi-omics data, offering a pathway toward personalized prognostic scoring. We also address the clinical transition of peripheral biomarkers (e.g. blood-based methylation assays) as surrogates for central nervous system pathology. The future of FXS management lies in 'precision prognosis.' By decoding the epigenetic markers that precede and accompany cognitive decline, clinicians can move toward earlier diagnosis and targeted interventions. This review outlines a strategic roadmap for standardizing epigenetic assays, highlighting their potential to revolutionize the predictive landscape of neurodevelopmental disorders.